Arnfinn Sundsfjord

We have evaluated the performance of FilmArray BCID2 in reactive blood cultures in a small acute care hospital compared to conventional diagnostics at a regional microbiological laboratory. This is a retrospective observational study of BactAlert reactive blood cultures ( n = 160) from Helgeland Hospital, July–December 2021, analysed by BCID2 locally and conventional culture at a regional laboratory. The overall clinical and analytic sensitivity with BCID2 were 87.2% and 97.8%, respectively. The false‐negative BCID2 rate was low ( n = 4; 2.9%). No false‐positive BCID2 results were observed. The BCID2 data were available on average 1.88 days earlier than culture‐based results, due to long transport time to the regional laboratory. The BCID2 provided results to support a significantly earlier optimized targeted antibiotic treatment in 27% of the cases according to national guidelines for empirical treatment of BSI. The high clinical and analytical sensitivity, and specificity support the use of BCID2 as a robust supplement to traditional cultivation of positive blood cultures. The significant time gain to microbial identification and detection of resistance determinants suggests a great clinical importance of BCID2 in small acute care hospitals with long transport time to conventional clinical microbiology services.